<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="111103">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02104765</url>
  </required_header>
  <id_info>
    <org_study_id>15435</org_study_id>
    <secondary_id>I5Q-MC-CGAE</secondary_id>
    <nct_id>NCT02104765</nct_id>
  </id_info>
  <brief_title>A Study of LY2951742 in Healthy Japanese and Caucasian Participants</brief_title>
  <official_title>A Single and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LY2951742 Administered Subcutaneously to Japanese and Caucasian Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to evaluate the safety of the study drug known as
      LY2951742 in healthy Japanese and Caucasians.  The study will also investigate how the body
      processes the drug and how the drug affects the body.  The study is expected to last about 5
      to 8 months, depending on the arm.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">January 2015</completion_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration</measure>
    <time_frame>Screening through Day 225</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Concentration of LY2951742</measure>
    <time_frame>Predose on Day 1 through Day 225</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration Curve of LY2951742</measure>
    <time_frame>Predose on Day 1 through Day 225</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Migraine Disorders</condition>
  <arm_group>
    <arm_group_label>LY2951742 Single Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 1 of LY2951742 given subcutaneously once</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY2951742 Single Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 2 of LY2951742 given subcutaneously once</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY2951742 Single Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 3 of LY2951742 given subcutaneously once</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY2951742 Single Dose 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose 4 of LY2951742 given subcutaneously once</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY2951742 Multiple Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY2951742 given subcutaneously once every 4 weeks for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Single Dose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo given subcutaneously once</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Multiple Dose</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo given subcutaneously once every 4 weeks for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY2951742</intervention_name>
    <description>Administered subcutaneously.</description>
    <arm_group_label>LY2951742 Single Dose 1</arm_group_label>
    <arm_group_label>LY2951742 Single Dose 2</arm_group_label>
    <arm_group_label>LY2951742 Single Dose 3</arm_group_label>
    <arm_group_label>LY2951742 Single Dose 4</arm_group_label>
    <arm_group_label>LY2951742 Multiple Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered subcutaneously.</description>
    <arm_group_label>Placebo Single Dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants are either Caucasian or first generation Japanese.

          -  Participants' body mass index (BMI) is between 18.0 and 35.0 kilogram per meter
             square (kg/ m^2).

        Exclusion Criteria:

          -  Participants are heavy caffeine drinkers defined by regular intake of more than 5
             cups of coffee (or equivalent in xanthine containing beverages) per day, and/or are
             unable or unwilling to abide by caffeine restrictions as specified in the protocol.

          -  Participants are smoking within the previous 6 months.

          -  Participants have received treatment with biologic agents (such as monoclonal
             antibodies) within 3 months or 5 half-lives (whichever is longer) prior to dosing or
             have received a vaccination within 1 month.

          -  Participants have known allergies to LY2951742, related compounds or any components
             of the formulation, or history of significant atopy.

          -  Participants are allergies to either humanized monoclonal antibodies,
             diphenhydramine, epinephrine, or methylprednisolone.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or</last_name>
    <phone>1-317-615-4559</phone>
  </overall_contact>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Cypress</city>
        <state>California</state>
        <zip>90630</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eli Lilly</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 30, 2014</lastchanged_date>
  <firstreceived_date>April 2, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
